Ryvu
Ryvu Therapeutics is a clinical-stage biopharmaceutical company developing first-in-class small molecule oncology therapies targeting CDK8/19, PIM/FLT3, and PRMT5. Headquartered in Kraków, Poland, it serves patients with hematologic malignancies and solid tumors through wholly-owned and partnered clinical programs.
- Company typePublic
- Founded2007
- HeadquartersKrakow, Poland
- Headcount251–500
- GTM typeB2B
- OfferingHardware or Manufacturing
What Ryvu does
Ryvu Therapeutics S.A. is a clinical-stage biopharmaceutical company headquartered in Kraków, Poland, founded in 2007 (formerly Selvita S.A.) and listed on the Warsaw Stock Exchange under ticker RVU. It develops first-in-class small molecule therapies addressing emerging oncology targets, with a portfolio led by romaciclib (RVU120/SEL120), an oral CDK8/19 inhibitor in Phase II for relapsed/refractory acute myeloid leukemia (RIVER-81), myelofibrosis (POTAMI-61) and low-risk MDS (REMARK), and dapolsertib (MEN1703/SEL24), a dual PIM/FLT3 inhibitor in Phase II for diffuse large B-cell lymphoma (JASPIS-01). The preclinical pipeline includes RVU305, a brain-permeable MTA-cooperative PRMT5 inhibitor for MTAP-deleted tumors, alongside STING-based antibody-drug conjugates licensed to Exelixis and an emerging ADC payload program.
The company's discovery engine rests on two proprietary platforms: ONCO Prime, which integrates patient-derived models, engineered systems and high-throughput CRISPR/omics analytics with machine learning to identify synthetic-lethal vulnerabilities in genetically stratified cancers; and PERO, which performs functional validation of structural protein pockets to support rational drug design. A team of roughly 230 employees including 90 PhD holders, supported by an international patent portfolio covering CDK8, MELK, A2A/A2B adenosine receptor and STING agonist chemistries, underwrites the R&D base.
Ryvu is pre-commercial and does not generate product revenue. Operating revenues of EUR 20.7M in FY2025 and EUR 5.1M in Q1 2026 consist of research collaboration reimbursements, clinical milestone payments and non-dilutive grants from European institutions including the European Investment Bank, the Medical Research Agency (ABM), the National Centre for Research and Development (NCBR) and EU regional funds. Strategic commercialization is structured around out-licensing and co-development with major pharma partners — BioNTech (research collaboration extended to November 2028), Exelixis (STING ADCs) and Menarini Group (dapolsertib) — with potential for direct sales upon regulatory approval of romaciclib or other wholly-owned assets.
Ryvu firmographics
Firmographics- Name
- Ryvu
- Legal name
- Ryvu Therapeutics S.A.
- Website
- https://ryvu.com/
- Company type
- Public
- Founded year
- 2007
- Operating status
- Operating
- Headcount range
- 251–500 employees
- Short description
- Ryvu Therapeutics is a clinical-stage biopharmaceutical company developing first-in-class small molecule oncology therapies targeting CDK8/19, PIM/FLT3, and PRMT5. Headquartered in Kraków, Poland, it serves patients with hematologic malignancies and solid tumors through wholly-owned and partnered clinical programs.
- Ownership category
- akta.pro rank
Ryvu industry classification
Industry- Product category
- Clinical-Stage Oncology Therapeutics
- NAICS
- Research and Development in Biotechnology (except Nanobiotechnology) (541714), Research and Development in the Physical, Engineering, and Life Sciences (54171)
- SIC
- Pharmaceutical Preparations (2834)
- akta.pro primary industry
- Drug Discovery (Target ID/Validation & Hit Discovery) (HLAIALAA)
- akta.pro secondary industry
- Target Identification & Validation Platforms (omics-driven, chemoproteomics, genetic validation) (HLAAAIAI)
Keywords
Where Ryvu is headquartered
LocationHeadquarters
- HQ city
- Krakow
- HQ country
- Poland
- HQ region
- Europe
Offices1 record
Markets served
Ryvu business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Personnel, Technology or R&D, Operations, Marketing or Sales, Supply Chain
Revenue model
- Partnership Revenue: Ryvu generates revenue through research collaborations and licensing agreements with pharmaceutical partners including BioNTech, Exelixis, and Menarini Group. Partners reimburse Ryvu for expenses and the company can receive multiple milestone payments.
- Grant Funding: Non-dilutive funding from government agencies including European Investment Bank (EUR 22 million venture debt), National Centre for Research and Development (NCBR), Medical Research Agency (ABM), and European Union regional funds. Q1 2026: EUR 5.1 million operating revenues including grants.
- Clinical Milestones: Revenue recognition from milestones achieved in clinical programs and collaborations, including RVU120 Phase II progress triggering EIB funding disbursement.
Go-to-market motion1 record
Distribution channels1 record
Marketing channels5 records
Ryvu product offering
Product offeringCore offering
Ryvu Therapeutics is a clinical-stage biopharmaceutical company that discovers and develops novel small molecule therapies targeting emerging oncology pathways, including CDK8/19, PIM/FLT3, and PRMT5. Its pipeline focuses on hematologic malignancies and selected solid tumors, with drug candidates advancing through preclinical and clinical stages (Phases 1 and 2). The company leverages proprietary discovery platforms to identify first-in-class therapeutic candidates for partnering or further development.
Product overview
Ryvu Therapeutics is a clinical-stage biopharmaceutical company developing a portfolio of small molecule oncology therapies with diverse therapeutic mechanisms. The core clinical programs include romaciclib (RVU120), a first-in-class CDK8/19 inhibitor with multiple Phase II trials in hematologic malignancies (RIVER-81 for AML, POTAMI-61 for myelofibrosis, REMARK for LR-MDS), and dapolsertib (MEN1703), a dual PIM/FLT3 kinase inhibitor in Phase II for DLBCL. The preclinical pipeline features RVU305 (MTA-cooperative PRMT5 inhibitor) and early discovery programs in ADCs with novel payloads. Discovery capabilities include the ONCO Prime precision oncology platform for synthetic lethal target identification and the PERO platform for functional target validation.
Differentiator
Problem solved
Functional benefit
Brands
- ONCO Prime: Precision oncology discovery platform leveraging patient-driven models, engineered systems, and high-throughput CRISPR/omics analytics for identification of synthetic lethal targets in genetically stratified cancers
- PERO
- ADCraft
Products and services
- Romaciclib (RVU120)
Quantifiable outcome
- 43% CR/CRi rate in RIVER-81 study at recommended dose of 150mg QD romaciclib + venetoclax
- +4 more outcomes
Companies that use Ryvu
Customer profileNamed customers5 records
Segments8 records
Ideal customer profiles2 records
Ryvu technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
AI capability4 records
Feature7 records
Ryvu partnerships and signals
Strategic signalPartnerships
Six partnerships are on record, tiered core and minor.
- BioNTechcoreResearch collaboration and exclusive license option agreement originally disclosed in November 2022. In March 2026, the collaboration was extended by one year until November 2028. In September 2025, the collaboration was expanded to support BioNTech in accelerating site activation and patient enrollment for priority oncology clinical programs in Poland including lung, breast, and colorectal cancers. Ryvu supports BioNTech's clinical trials and is reimbursed for expenses with potential for milestone payments.
- Children's Memorial Health InstituteminorCollaboration initiated September 2025 as part of MEDWAY project, an investigator-initiated Phase I clinical study evaluating romaciclib in combination with everolimus in children with recurrent or progressive medulloblastoma. First patient first visit expected Q2 2026.
- Menarini GroupcoreJASPIS-01 Phase II study of dapolsertib (MEN1703/SEL24) for r/r DLBCL is fully funded by Menarini Group and operationally executed by Ryvu. First patient dosed March 2025.
- ExelixiscoreExclusive license agreement with Exelixis for STING ADC technology. Ryvu develops STING-based antibody-drug conjugates for targeted cancer therapy under this partnership.
- EMSCOminorPartnership for REMARK study - Phase II investigator-initiated trial of romaciclib in low-risk MDS. EMSCO provides funding and operational support.
- BCUnitedminorPartnership for RIVER-81 study in relapsed/refractory AML. BCUnited provides funding and operational support for clinical development.
Scale indicators16 records
Recent moves6 records
Expansion highlights4 records
Ryvu competitors and assessment
Company assessmentDirect peers
- Werewolf Therapeutics: US clinical-stage oncology biotech developing conditionally activated therapeutics. Comparable as a small-cap clinical-stage oncology company with platform-driven pipeline development.
- Bicycle Therapeutics: Clinical-stage UK biotech developing precision oncology therapeutics using bicyclic peptide technology. Comparable as a clinical-stage oncology company advancing novel modalities toward Phase II readouts with partnership revenue.
- Foghorn Therapeutics: US clinical-stage oncology biotech targeting chromatin regulatory biology with small molecules. Comparable to Ryvu's transcriptional regulation focus and similar Phase II-stage portfolio profile.
- Syros Pharmaceuticals: US clinical-stage precision oncology biotech using gene regulation platforms to develop small molecule therapies. Comparable in targeting transcriptional dysregulation and hematologic/oncology indications.
- Tempest Therapeutics: US clinical-stage immuno-oncology biotech developing small molecule therapies. Comparable in scale, clinical stage, and oncology small molecule focus.
- Kronos Bio: US clinical-stage oncology biotech developing small molecule therapies targeting dysregulated transcription and cell signaling. Closely comparable to Ryvu's CDK8/19 transcriptional regulation approach and Phase II hematology focus.
- Aprea Therapeutics: US clinical-stage oncology biotech focused on small molecule therapeutics targeting DNA damage response and synthetic lethality. Directly comparable to Ryvu's synthetic lethality and DDR-adjacent pipeline.
- BerGenBio: Norway-headquartered clinical-stage oncology biotech developing selective kinase inhibitors in hematologic and solid tumors. Highly comparable to Ryvu in size, stage, and kinase-targeting approach.
Broad incumbents
- Schrödinger: US computational drug discovery platform serving multiple therapeutic areas including oncology. Broader and more established than Ryvu but relevant given overlapping computational/discovery approaches to small molecule design.
Emerging players
- Recursion Pharmaceuticals: US AI-enabled drug discovery company developing pipeline across oncology and rare diseases. Comparable as a technology-driven drug discovery company, though with broader scope and larger capital base.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat5 records
Key risks6 records
Key highlights7 records
Customer concentration
Ryvu social profiles
Digital presenceRyvu financial estimates
Financial estimateRevenue estimate
Valuation estimate
Ryvu leadership team
Management profileNumber of profiles
Profiles6 records
Ryvu funding detail
Funding detailFunding overview
Funding rounds7 records
Investors5 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Ryvu M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Ryvu
What does Ryvu do?
Ryvu Therapeutics is a clinical-stage biopharmaceutical company that discovers and develops novel small molecule therapies targeting emerging oncology pathways, including CDK8/19, PIM/FLT3, and PRMT5. Its pipeline focuses on hematologic malignancies and selected solid tumors, with drug candidates advancing through preclinical and clinical stages (Phases 1 and 2). The company leverages proprietary discovery platforms to identify first-in-class therapeutic candidates for partnering or further development.
Is Ryvu a public or private company?
Ryvu is a public company. It is classified as public and is currently operating.
When was Ryvu founded?
Ryvu was founded in 2007. It employs 251 to 500 people.
Where is Ryvu based?
Ryvu is headquartered in Krakow, Poland, in the Europe region.
How does Ryvu make money?
Three revenue lines are on record. Partnership Revenue is the primary driver. The others are grant Funding and clinical Milestones.
Who are Ryvu's main competitors?
Direct peers on record are Werewolf Therapeutics, Bicycle Therapeutics, Foghorn Therapeutics, Syros Pharmaceuticals, Tempest Therapeutics, Kronos Bio, Aprea Therapeutics and BerGenBio. Schrödinger is listed as a broad incumbent. Recursion Pharmaceuticals is listed as an emerging player.
Does Ryvu have an API?
No public API is recorded for Ryvu.
What industry is Ryvu in?
Ryvu's product category is Clinical-Stage Oncology Therapeutics. Its primary akta.pro industry code is HLAIALAA, Drug Discovery (Target ID/Validation & Hit Discovery), with a secondary code of HLAAAIAI, Target Identification & Validation Platforms (omics-driven, chemoproteomics, genetic validation). Its NAICS code is 541714 and its SIC code is 2834.